Latest disorders Stories
SAN DIEGO, April 28, 2011 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease. Study results showed OTO-104 to be well-tolerated at both doses tested when delivered via a single intratympanic (IT) injection. Additionally, while not powered to...
WAYNE, N.J., April 14, 2011 /PRNewswire/ -- To help raise money and awareness for bleeding disorders, Bayer is launching the 2011 Bayer Virtual Walk for Hemophilia, the first interactive program of its kind in support of people with hemophilia. The Virtual Walk is Bayer's latest digital offering for the hemophilia community. The company is asking people to step up for an important cause by virtually walking online for the National Hemophilia Foundation (NHF) and its local participating...
NEW YORK, March 29, 2011 /PRNewswire-USNewswire/ -- United Spinal Association and National Spinal Cord Injury Association (NSCIA), two leading nonprofits with more than 125 years of combined service to the disability community, have recently announced their intended merger unifying resources to become the single, largest membership organization dedicated to improving the lives of people with spinal cord injuries and disorders (SCI/D) nationwide. The combined organization will significantly...
The discovery at Scripps Research could usher in a new way of designing non-toxic drugs, researchers sayOver the last years, two teams of researchers at The Scripps Research Institute have steadily built a model of how a powerful DNA repair complex works. Now, their latest discovery provides revolutionary insights into the way the molecular motor inside the complex functions "“ findings they say may have implications for treatment of disorders ranging from cancer to cystic fibrosis.In a...
SEATTLE, March 23, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary...
SEATTLE, March 15, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010. Financial Results Total operating expenses for the three months ended December 31, 2010 were $9.5 million, compared to $5.7 million for the same period in...
(Ivanhoe Newswire) -- Did you know that more than 8,000,000 people in the United States have an eating disorder? And the worst thing about this disorder is that it isn't even the most detrimental disorder involved. Eating disorder's severity and dramatic effects have been continually demonstrated through elevated rates of impairment, medical complications, other illnesses, death and suicide.Despite the fact that the lifetime prevalence estimates of eating disorders from...
ST. LOUIS, Feb. 24, 2011 /PRNewswire/ -- Vision plays an important role in many aspects of daily life. From morning to night, the eyes are working hard to process information. In fact, according to the American Optometric Association's (AOA) American Eye-Q® survey, 46 percent of consumers indicate eyesight is the sense they worry most about losing. With consumer sentiment so focused on eye health, protecting the eyes and vision should be an important part of overall health care for...
NIH funded study has implications for understanding disorders of the uterusResearchers funded by the National Institutes of Health have identified a key step in the establishment of a pregnancy. Their discovery shows how the hormone progesterone suppresses the growth of the uterus's lining so that a fertilized egg can implant in the uterus.This key step, the researchers discovered, occurs when a protein called Hand2 suppresses the chemical activity that stimulates growth of the uterine...
PRINCETON, N.J., Feb. 4, 2011 /PRNewswire/ -- Novo Nordisk announced today the availability of Coags Uncomplicated - the first mobile application (app) to assist in the diagnosis of bleeding disorders - created in partnership with Craig Kessler, MD, Professor of Medicine and Pathology and Director of the Coagulation Laboratory, Georgetown University Hospital, Lombardi Comprehensive Cancer Center. Coags Uncomplicated features a Lab Value Analyzer that enables physicians to input test results...
